The Rationale for Glutamate Antagonists in the Treatment of Traumatic Brain Injury

J. S. MYSEROS, R. BULLOCK

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

The recent development of potent antagonists for the most widespread neurotransmitter in the mammalian brain has opened up possibilities for many forms of therapy. The excitotoxic hypothesis implicates excessive release of excitatory amino acids (EAAs) as an important cause of brain damage, especially in acute ischemia, and chronic neurodegeneration. Focal ischemic damage and diffuse axonal injury are the major causes of brain damage after traumatic human brain injury. Evidence from animal models has shown that excitatory amino acid-induced events maybe responsible for a proportion of the posttraumatic sequelae and that these effects can be blocked by EAA antagonists. This evidence is reviewed, and the implications for human pathophysiology and treatment are discussed.

Original languageEnglish (US)
Pages (from-to)262-271
Number of pages10
JournalAnnals of the New York Academy of Sciences
Volume765
Issue number1
DOIs
StatePublished - Sep 1995

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Fingerprint Dive into the research topics of 'The Rationale for Glutamate Antagonists in the Treatment of Traumatic Brain Injury'. Together they form a unique fingerprint.

  • Cite this